Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Quality of life EORTC QLQ‐C30 · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Quality of life EORTC QLQ‐BN 20 · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Porter 2020: armodafinil vs placebo Fatigue Brief Fatigue Inventory (number of participants with an improvement in 2 points from baseline at 8 weeks (%)) · people with primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 297 participants | Low |
Boele 2013: modafinil vs placebo Fatigue –reduced motivation Subscale from CIS · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 37 participants | Very low |
Porter 2020: armodafinil vs placebo Cognition Symbol Digit Modalities Test (median (range)) · people with primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 180 participants | Low |
Porter 2020: armodafinil vs placebo Quality of life Linear Analogue Self Assessment (median (range)) · people with primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 232 participants | Low |
Porter 2020: armodafinil vs placebo Adverse events Grade 3 or higher (number of participants (%)) · people with primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 328 participants | Low |
Boele 2013: modafinil vs placebo Fatigue –reduced activity Subscale from CIS · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 37 participants | Very low |
Boele 2013: modafinil vs placebo Fatigue –severity Subscale from CIS · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 37 participants | Very low |
Boele 2013: modafinil vs placebo Adverse events ( · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | RR 2.79 [0.59, 13.16] | 1 study · 37 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Fatigue MFI‐20 scale ( · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Fatigue ('asthenia') Norris Scale · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Cognition Trail Making Test A · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Cognition Trail Making Test B · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin Progression‐free survival (PFS) · first‐line treatment of ovarian cancer Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial… (2022) · Cochrane | HR 0.89 [0.81, 0.98] | 4 studies · 3699 participants | Moderate |
Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin Overall survival (OS) · first‐line treatment of ovarian cancer Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial… (2022) · Cochrane | HR 0.92 [0.79, 1.06] | 4 studies · 3699 participants | High |
Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin Haematological adverse event: Grade 3/4 neutropenia · first‐line treatment of ovarian cancer Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial… (2022) · Cochrane | RR 1.11 [0.86, 1.43] | 4 studies · 3639 participants | Moderate |
Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin Haematological adverse event: Grade 3/4 anaemia · first‐line treatment of ovarian cancer Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial… (2022) · Cochrane | RR 1.57 [1.12, 2.2] | 4 studies · 3639 participants | High |
Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial… (2022) · Cochrane | RR 1.12 [0.64, 1.94] | 4 studies · 3639 participants | Low |
Intervention NR Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MS · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Intervention NR NanoString · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Intervention NR Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR FISH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 15 studies · 915 participants | Low |
Intervention NR Real‐time PCR · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Intervention NR MLPA · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Intervention NR CGH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 6 studies · 151 participants | Low |
Intervention NR aCGH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 4 studies · 57 participants | High |
Intervention NR SNP array · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 2 studies · 33 participants | Very low |
Intervention NR NGS · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 49 participants | Very low |
Intervention NR CISH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 38 participants | High |
Intervention NR MS · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 50 participants | Very low |
Intervention NR G‐banding · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
Intervention NR PCR‐based LOH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 15 studies · 915 participants | Low |
Intervention NR Real‐time PCR · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 2 studies · 40 participants | Very low |
Intervention NR MLPA · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 2 studies · 33 participants | Very low |
Intervention NR CGH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 4 studies · 75 participants | Low |
Intervention NR aCGH · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 3 studies · 39 participants | Very low |
Intervention NR SNP array · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 6 studies · 111 participants | Very low |
Intervention NR NGS · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | 6 studies · 243 participants | Low |
Intervention NR Cognitive function using validated neuropsychological tests · patients with a primary brain tumour, within two weeks of surgical intervention Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and… (2022) · Cochrane | no estimate extracted | 1 study · 53 participants | Very low |
Pre‐emptive antifungal therapy vs empirical antifungal therapy All‐cause mortality · people with cancer who have febrile neutropenia Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with… (2022) · Cochrane | RR 0.97 [0.72, 1.3] | 6 studies · 1459 participants | Low |
Pre‐emptive antifungal therapy vs empirical antifungal therapy Mortality ascribed to fungal infection · people with cancer who have febrile neutropenia Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with… (2022) · Cochrane | RR 0.92 [0.45, 1.89] | 5 studies · 1407 participants | Low |
Pre‐emptive antifungal therapy vs empirical antifungal therapy Proportion of antifungal agent use (other than prophylactic use) · people with cancer who have febrile neutropenia Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with… (2022) · Cochrane | RR 0.71 [0.47, 1.05] | 7 studies · 1480 participants | Very low |
Pre‐emptive antifungal therapy vs empirical antifungal therapy Duration of antifungal use (days) · people with cancer who have febrile neutropenia Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with… (2022) · Cochrane | no estimate extracted | 3 studies · 764 participants | Very low |
Pre‐emptive antifungal therapy vs empirical antifungal therapy Invasive fungal infection detection · people with cancer who have febrile neutropenia Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with… (2022) · Cochrane | RR 1.7 [0.71, 4.05] | 7 studies · 1480 participants | Very low |
Pre‐emptive antifungal therapy vs empirical antifungal therapy Adverse effects · people with cancer who have febrile neutropenia Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with… (2022) · Cochrane | no estimate extracted | 4 studies · 1074 participants | Very low |
Dexrazoxane vs no cardioprotective intervention or placebo Clinical heart failure Available case analysis · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | RR 0.22 [0.11, 0.43] | 7 studies · 1221 participants | Moderate |
Dexrazoxane vs no cardioprotective intervention or placebo Secondary malignant neoplasms · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Clinical heart failure Available‐case analysis · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | RR 0.2 [0.01, 4.19] | 3 studies · 885 participants | Low |